Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2026)

Upstream Bio's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $318.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 30.28% year-over-year to $318.1 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 26.73% YoY), while the FY2025 annual figure was $353.8 million, down 26.56% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $318.1 million, down from $353.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $481.7 million in Q4 2024, with the low at $117.2 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $372.5 million (2025), against an average of $346.4 million.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity soared 311.03% in 2024, then plunged 30.28% in 2026.
• Upstream Bio's Liabilities and Shareholders Equity stood at $117.2 million in 2023, then soared by 311.03% to $481.7 million in 2024, then retreated by 26.56% to $353.8 million in 2025, then dropped by 10.1% to $318.1 million in 2026.
• Business Quant data shows UPB's Liabilities and Shareholders Equity at $318.1 million in Q1 2026, $353.8 million in Q4 2025, and $391.2 million in Q3 2025.